Polymorphisms in the IFNAR1 gene in patients with chronic hepatitis C: outcome of combined IFN-alpha therapy

Eur Cytokine Netw. 2007 Sep;18(3):136-41. doi: 10.1684/ecn.2007.0098. Epub 2007 Sep 7.


Aims: Interferon-alpha (IFN-alpha) alone or in combination with ribavirin has been used for the last decade in the treatment of chronic hepatitis C, although the achievement of a sustained virological response (SVR) has not been very satisfactory. The treatment outcome depends on viral genotypes and host genetic polymorphisms in genes involved in the IFN-alpha signaling cascade. In this paper, we investigated the distribution of two variants of the IFNAR1 gene, G17470C and L168V, in two patient groups having received IFN-alpha alone or in combination with ribavirin.

Methods: The analysis was performed using DNA sequencing of the relevant gene fragments.

Results and conclusions: This study suggests that when combination therapy with high dose IFN-alpha and ribavirin is administered, HCV genotypes and age rather than the IFNAR1 polymorphisms are the predictors of a sustained response.

MeSH terms

  • Adult
  • Age Factors
  • Antiviral Agents / therapeutic use*
  • Brazil / epidemiology
  • DNA / blood
  • DNA / isolation & purification
  • Drug Therapy, Combination
  • Female
  • Genome, Viral*
  • Genotype
  • Hepacivirus / drug effects
  • Hepacivirus / physiology
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / epidemiology
  • Hepatitis C, Chronic / genetics*
  • Hepatitis C, Chronic / virology
  • Humans
  • Interferon Type I / therapeutic use*
  • Male
  • Middle Aged
  • Polymorphism, Genetic*
  • RNA, Viral / analysis
  • Receptor, Interferon alpha-beta / genetics*
  • Recombinant Proteins
  • Remission Induction
  • Ribavirin / therapeutic use
  • Sequence Analysis, DNA / methods
  • Treatment Outcome


  • Antiviral Agents
  • Interferon Type I
  • RNA, Viral
  • Recombinant Proteins
  • Receptor, Interferon alpha-beta
  • Ribavirin
  • DNA